These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 30414440)

  • 1. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
    Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
    Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma.
    Pelaia G; Gallelli L; Romeo P; Renda T; Busceti MT; Proietto A; Grembiale RD; Marsico SA; Maselli R; Vatrella A
    Int J Clin Pharmacol Ther; 2011 Dec; 49(12):713-21. PubMed ID: 22122813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
    Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
    Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
    Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
    Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
    Respir Med; 2019; 154():69-75. PubMed ID: 31220806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The real world effect of omalizumab add on therapy for patients with moderate to severe allergic asthma: The ASTERIX Observational study.
    Bhutani M; Yang WH; Hébert J; de Takacsy F; Stril JL
    PLoS One; 2017; 12(8):e0183869. PubMed ID: 28859150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
    Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
    Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
    Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
    Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
    Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
    Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
    Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
    Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study.
    Solidoro P; Patrucco F; de Blasio F; Brussino L; Bellocchia M; Dassetto D; Pivetta E; Riccio A; Heffler E; Canonica W; Rolla G; Bucca C
    Ther Adv Respir Dis; 2019; 13():1753466619841274. PubMed ID: 31002021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
    Kavati A; Zhdanava M; Ortiz B; Lecocq J; Schiffman B; Pilon D; Ho H; Lefebvre P; Stone B
    Clin Ther; 2019 Oct; 41(10):1956-1971. PubMed ID: 31563391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study.
    Detoraki A; Di Capua L; Varricchi G; Genovese A; Marone G; Spadaro G
    J Asthma; 2016; 53(2):201-6. PubMed ID: 26377630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to omalizumab in patients with severe allergic asthma: A real-life study.
    Zierau L; Walsted ES; Thomsen SF; Backer V
    Respir Med; 2017 Oct; 131():109-113. PubMed ID: 28947015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma.
    Busse WW; Humbert M; Haselkorn T; Ortiz B; Trzaskoma BL; Stephenson P; Garcia Conde L; Kianifard F; Holgate ST
    Ann Allergy Asthma Immunol; 2020 Feb; 124(2):190-196. PubMed ID: 31760132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Real-life" Efficacy and Safety Aspects of 4-Year Omalizumab Treatment for Asthma.
    Al-Ahmad M; Arifhodzic N; Nurkic J; Maher A; Rodriguez-Bouza T; Al-Ahmed N; Sadek A; Jusufovic E
    Med Princ Pract; 2018; 27(3):260-266. PubMed ID: 29414831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
    Dal Negro RW; Tognella S; Pradelli L
    J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.